Skip to main content
NewslettersWatchlist

Pharmala Biotech Holdings Inc.(MDMA-CN)
CSE

Today's Change
Delayed Last Update
Day Low0.1900
Day High0.2300
Open:0.1900
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
GlobeNewswire
PharmAla Closes Private Placement and Concurrent Debt Settlement
GlobeNewswire
PharmAla Announces Private Placement and Concurrent Debt Settlement
GlobeNewswire
PharmAla Biotech Signs Sale Agreement with Numinus
GlobeNewswire
PharmAla Announces Voting Results of Annual General and Special Meeting of Shareholders and Provides Corporate Update
Newsfile
Red Light Holland Commences Experimental Research on Psilocybin Truffles to Develop Process for Commercial Manufacturing of Natural-Source Active Pharmaceutical Ingredient
GlobeNewswire
PharmAla named an Intellectual Property Ontario Client
GlobeNewswire
PharmAla Data to be Published in ACS Chemical Neuroscience
GlobeNewswire
PharmAla and Red Light Holland to Collaborate on Medical Psilocybin Development
GlobeNewswire
PharmAla releases Profitable Q1 Interim Financial Statement and Business Update
GlobeNewswire
PharmAla granted a Controlled Drugs & Substances Dealer’s License by Health Canada
GlobeNewswire
PharmAla Files Audited Financials for Year Ending August 31, 2023
GlobeNewswire
PharmAla Biotech and Filament Health Announce Release of Second Batch of GMP MDMA Capsules
GlobeNewswire
World’s First Observational Trial to Assess Real-World Efficacy of MDMA Treatment
GlobeNewswire
PharmAla Partners with Clariti Strategic Advisors™
GlobeNewswire
PharmAla Completes Historic First Shipment of MDMA and Psilocybin to Cortexa
GlobeNewswire
PharmAla Receives First Office Action for PharmAla-1 PCT Filing
GlobeNewswire
PharmAla Ships MDMA to Mind Medicine Australia and Orygen Institute
GlobeNewswire
PharmAla Received Guidance on ALA-002 from MHRA; Launches Clinical Program with University of Sydney
GlobeNewswire
Cortexa Makes First Drug Order for Australian Commercial Market
GlobeNewswire
PharmAla Biotech Receives Export Permit to Ship GMP LaNeo MDMA to the University of Sydney
GlobeNewswire
PharmAla Biotech announces Non-Brokered Private Placement Offering of up to an Aggregate of $5,000,000
GlobeNewswire
PharmAla Awarded Research Grant by Ontario Centre for Innovation
Newswire.ca
FILAMENT HEALTH AND PHARMALA BIOTECH ANNOUNCE RELEASE OF GMP MDMA CAPSULES
ACCESSWIRE
The Power Play by The Market Herald Releases New Interviews with Pharmala Biotech Holdings, Nextech AR Solutions and Enertopia Discussing Their Latest News
Newswire.ca
PharmAla appoints Dr. Leah Mayo to Scientific Advisory Board
Newswire.ca
PharmAla Contracts with Clerkenwell to bring safer MDMA analogue to US, UK
Newswire.ca
PharmAla Biotech ready to assist Alberta Government with Clinical MDMA supply
Baystreet
Stocks in play: Pharmala Biotech Holdings Inc
Baystreet
Stocks in play: Pharmala Biotech Holdings Inc
Newswire.ca
PharmAla Biotech completes filing of Patent application for 6 MDMA analogs
Newswire.ca
PharmAla Biotech First Publicly Traded Company to Produce GMP MDMA
Baystreet
Stocks in play: Pharmala Biotech Holdings Inc

Profile

Pharmala Biotech Holdings Inc is focused on manufacturing and sales of MDMA and MDXX Active Pharmaceutical Ingredients (API) for use in clinical research. PharmAla's drug API is manufactured and encapsulated under GMP conditions. The Company generates revenue from the sale of tablets and raw MDMA and MDXX compounds/formulations.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.